Invagen Pharmaceuticals has entered into a strategic partnership with Qilu Pharmaceutical Co, for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for the United States.
As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA will be responsible for the commercialisation of the asset by leveraging its strong commercial presence in the defined territory.
The collaboration reflects both companies’ shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.
